Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9627340 | 0.76 | HPGD (0.66) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8574458 | 0.74 | LMNA (0.35) | MEN1KMT2APOLBALDH1A1LMNA | |
| SCHEMBL432918 | 0.70 | MEN1 (0.54) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25329754 | 0.69 | ALDH1A1 (0.37) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29946500 | 0.68 | MEN1 (0.50) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL678115 | 0.68 | MEN1 (0.50) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL677619 | 0.68 | MEN1 (0.50) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6949386 | 0.68 | MEN1 (0.50) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8164410 | 0.68 | MEN1 (0.50) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3612810 | 0.68 | OPRM1 (0.48) | MEN1KMT2ASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242150-B2 | Triazole derivatives for treating alzheimer'S disease and related conditions | MERCK SHARP & DOHME CORP. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100222320-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | SCHERING CORPORATION | 2010-09-02 | — | — | US | disclosed |
| EP-2166854-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008156580-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222320-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | BACE1, PSEN1, PSEN2 | MEN1 4201/4885KMT2A 2910/4885CYP1A2 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.